U.S. Markets open in 9 hrs 3 mins

Knight Therapeutics Inc. (GUD.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
5.270.00 (0.00%)
At close: 4:00PM EDT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.27
Open5.23
Bid5.27 x 0
Ask5.28 x 0
Day's Range5.23 - 5.29
52 Week Range4.88 - 8.08
Volume221,463
Avg. Volume375,531
Market Cap678.586M
Beta (5Y Monthly)0.69
PE Ratio (TTM)16.52
EPS (TTM)0.32
Earnings DateJun 24, 2021 - Jun 28, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.51
  • Knight to Present at the 2021 RBC Capital Markets Global Healthcare Conference
    GlobeNewswire

    Knight to Present at the 2021 RBC Capital Markets Global Healthcare Conference

    MONTREAL, May 12, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Operating Officer, is scheduled to participate in a fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on Tuesday, May 18, 2021 at 8:35 am ET. A live webcast of the event will be available at the following link: Event. A copy of the presentation will be available at www.gud-knight.com. About Knight Therapeutics Inc. Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing innovative pharmaceutical products for Canada and Latin America. Knight owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com. Forward-Looking Statement This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2020 as filed on www.sedar.com. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law. CONTACT INFORMATION: Investor Contact: Knight Therapeutics Inc. Samira SakhiaArvind UtchanahPresident & Chief Operating OfficerChief Financial OfficerT: 514.484.4483 ext.122T. 514.484.4483 ext. 115F: 514.481.4116F. 514.481.4116Email: info@knighttx.comEmail: info@knighttx.comWebsite: www.gud-knight.comWebsite: www.gud-knight.com

  • Notice of Knight Therapeutics' First Quarter 2021 Results Conference Call
    GlobeNewswire

    Notice of Knight Therapeutics' First Quarter 2021 Results Conference Call

    MONTREAL, May 07, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2021 financial results on Friday, May 14, 2021 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call. Date: Friday, May 14, 2021Time: 8:30 a.m. ETTelephone: Toll Free: 888-506-0062 or International 973-528-0011Webcast: www.gud-knight.com or WebcastThis is a listen-only audio webcast. Media Player is required to listen to the broadcast.Replay: An archived replay will be available for 30 days at www.gud-knight.com.About Knight Therapeutics Inc. Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing innovative pharmaceutical products for Canada and Latin America. Knight owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com. Forward-Looking Statement This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2020 as filed on www.sedar.com. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law. CONTACT INFORMATION: Investor Contact: Knight Therapeutics Inc.Samira SakhiaPresident and Chief Operating OfficerT: 514.484.4483 ext. 122 F: 514-481-4116Email: info@knighttx.comWebsite: www.gud-knight.comKnight Therapeutics Inc.Arvind UtchanahChief Financial OfficerT. 514.484.4483 ext. 115F. 514.481.4116Email: info@knighttx.comWebsite: www.gud-knight.com

  • Maverix Private Equity Announces Team Additions
    CNW Group

    Maverix Private Equity Announces Team Additions

    Maverix Private Equity, a Toronto-based private equity firm which recently announced an inaugural USD $500 million growth-fund, has today announced the addition of Michael Wasserman as a Managing Partner, joining Founder John Ruffolo and Mark Maybank. Michael is returning to Canada after 17 years at H.I.G Capital Management, a leading global private equity investment firm with more than $44 billion of equity capital under management. Most recently, Michael was a Managing Director of H.I.G. BioHealth Partners, the firm's dedicated healthcare investment fund, where Michael sourced, executed and managed a diverse investment portfolio of healthcare business across stages, sectors and geographies. Michael remains a Senior Advisor with H.I.G. In addition to his firm-wide responsibilities, Michael will be leading Maverix's investments in Healthcare and Wellness, one of the firm's core investment themes.